MedTrace Logo

Role of Famotidine in the Clinical Improvement of COVID-19 Patients.

NCT04504240 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2021-10-26

No results posted yet for this study

Summary

This study is aimed to investigate the effect of Famotidine in the clinical recovery of COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE came to the limelight due to its role in reducing the symptoms of COVID-19 patients. The study will include COVID-19 participants to confirm by RT PCR or an HRCT chest. Detail history of each participant with comorbidity will be taken and will be examined carefully. The hospitalized patients admitted to the HDU/ICU units will be enrolled in this study. Critically ill patients who require ventilator support will not be included in this study. The outcome of the Famotidine treatment will be evaluated and compared with a control group.

Conditions

  • Covid19

Interventions

DRUG

Famotidine 20 MG

Famotidine; tablet Famotac 20mg oral form.

Sponsors & Collaborators

  • M Abdur Rahim Medical College and Hospital

    collaborator OTHER_GOV

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Chattogram General Hospital

    lead OTHER_GOV

Principal Investigators

  • Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD · First Affiliated Hospital Xi'an Jiaotong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-04-15
Completion
2021-04-15

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504240 on ClinicalTrials.gov